- Home
- GENK vs RNXT Comparison
GENK vs RNXT Comparison
Compare GENK & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- RNXT
- Stock Information
- Founded
- GENK 2011
- RNXT 2012
- Country
- GENK United States
- RNXT United States
- Employees
- GENK N/A
- RNXT N/A
- Industry
- GENK Restaurants
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- RNXT Health Care
- Exchange
- GENK Nasdaq
- RNXT Nasdaq
- Market Cap
- GENK 20.4M
- RNXT 44.6M
- IPO Year
- GENK 2023
- RNXT 2021
- Fundamental
- Price
- GENK $3.80
- RNXT $1.30
- Analyst Decision
- GENK Strong Buy
- RNXT Strong Buy
- Analyst Count
- GENK 2
- RNXT 2
- Target Price
- GENK $10.00
- RNXT $7.25
- AVG Volume (30 Days)
- GENK 106.1K
- RNXT 169.3K
- Earning Date
- GENK 07-30-2025
- RNXT 08-12-2025
- Dividend Yield
- GENK 0.79%
- RNXT N/A
- EPS Growth
- GENK N/A
- RNXT N/A
- EPS
- GENK N/A
- RNXT N/A
- Revenue
- GENK $214,957,000.00
- RNXT $240,000.00
- Revenue This Year
- GENK $16.62
- RNXT $3,186.05
- Revenue Next Year
- GENK $20.40
- RNXT $291.93
- P/E Ratio
- GENK N/A
- RNXT N/A
- Revenue Growth
- GENK 14.40
- RNXT N/A
- 52 Week Low
- GENK $3.16
- RNXT $0.75
- 52 Week High
- GENK $10.33
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- GENK 42.84
- RNXT 55.53
- Support Level
- GENK $3.50
- RNXT $1.31
- Resistance Level
- GENK $3.78
- RNXT $1.42
- Average True Range (ATR)
- GENK 0.26
- RNXT 0.06
- MACD
- GENK -0.01
- RNXT -0.01
- Stochastic Oscillator
- GENK 22.64
- RNXT 56.25
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.